newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) projected 40% enrolled by the end of March; Company on track to complete enrollment by